Federal Trade Commission

FTC seeks information on proposed Actavis acquisition of Warner Chilcott

Monday, July 15, 2013

Actavis, a globally integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products, and Warner Chilcott, a supplier of inhalation drug development, delivery and supply capabilities, have both received a request for additional information from the Federal Trade Commission (FTC) in connection with Actavis’ pending acquisition of Warner Chilcott. The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”).

[Read More]